Clinical trials: Community-Acquired Infection
Community-acquired Pneumonia, Pneumonia
Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
- Trial name
- NCT06263881
- Testing
- Raphamin
- Where
- 38 sites in Russia
- Volunteers
- 370 people
- Sponsor
- Materia Medica Holding
Chronic Obstructive Pulmonary Disease, Community-acquired Pneumonia
A Pre-post Intervention Study Evaluating Home-based Management of Patients With COPD or CAP
Risk of rehospitalization within 30 days of discharge is higher than 20% in patients with chronic obstructive pulmonary disease (COPD) and up to 20% for patients with community acquired pneumonia (CAP).
- Trial name
- NCT05009485
- Testing
- Current Health platform
- Sponsor
- Current Health
Community-acquired Infection
An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects
GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA and is currently in development for the…
- Trial name
- NCT01267968
- Testing
- GSK2251052
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community-acquired Infection
A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study
GSK2251052 is a member of a novel mechanistic and structural class of antibiotics that inhibits the bacterial enzyme leucyl tRNA synthetase (LeuRS) by forming a boron adduct with tRNA and is currently in development for the…
- Trial name
- Relative Bio (NCT01702350)
- Testing
- GSK2251052
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sepsis, Community Acquired Pneumonia (CAP)
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to…
- Trial name
- NCT06669403
- Testing
- OPT101
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Op-T LLC
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Community Acquired Bacterial Pneumonia
Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.
- Trial name
- DEFINE-CABP (NCT02679573)
- Testing
- Delafloxacin, Moxifloxacin, Linezolid
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 860 people
- Sponsor
- Melinta Therapeutics, Inc.
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.
- Trial name
- NCT01886053
- Testing
- Faropenem（high dose group）, Faropenem（low-dose group), Ertapenem
- Where
- 9 sites in China
- Volunteers
- 189 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pneumonia
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days
A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia (CAP)…
- Trial name
- COBRA II (NCT00237445)
- Testing
- telithromycin, azithromycin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Sanofi
Community-Acquired Pneumonia
Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia
The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response.
- Trial name
- NCT00140023
- Testing
- Azithromycin microspheres 2.0 single dose
- Where
- 5 sites in Philippines
- Volunteers
- 47 people
- Sponsor
- Pfizer
Community-Acquired Infections
Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects
To purpose of this study is to assess the safety and tolerability of intravenous (IV) tigecycline in hospitalized subjects of Japanese descent with community-acquired pneumonia (CAP).
- Trial name
- NCT00575094
- Testing
- tigecycline
- Where
- 9 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community Acquired Pneumonia, Staphylococcal Skin Infections
First Time in Man Trial for Friulimicin B
The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine.
- Trial name
- NCT00492271
- Testing
- Friulimicin B
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH
Pneumonia
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients
The study was performed to see if a single, 2.0-g oral dose of azithromycin sustained release (SR) was at least as effective as a 7-day regimen of levofloxacin (500 mg once daily) for the treatment of mild to moderate…
- Trial name
- NCT00643734
- Testing
- azithromycin sustained release, levofloxacin
- Where
- 65 sites in United States, Canada and 6 more
- Volunteers
- 468 people
- Sponsor
- Pfizer
Pneumonia, Sepsis
A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
- Trial name
- NCT00042588
- Testing
- Recombinant Chimeric Monoclonal Antibody
- Where
- United States
- Sponsor
- ICOS Corporation
Infections
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant…
- Trial name
- NCT01645735
- Testing
- Ceftaroline fosamil, Ceftriaxone plus vancomycin
- Where
- 31 sites in United States, Georgia and 6 more
- Volunteers
- 49 people
- Sponsor
- Forest Laboratories
Community Acquired Pneumonia, Complicated Skin and Soft Tissue Infection
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue…
- Trial name
- NCT04198571
- Testing
- Zinforo (ceftaroline fosamil)
- Where
- 26 sites in Brazil, Colombia and 5 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Community-acquired Pneumonia
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
Through a series of retrospective analysis, it is hoped that an objective evaluation of the effect and safety of Eucalyptol, Limonene and Pinene Enteric Soft Capsules in the treatment of community-acquired pneumonia can be made.
- Trial name
- NCT05002192
- Testing
- Eucalyptol, Limonene and Pinene Enteric Soft Capsule, Ambroxol injection, Other oral mucolytic drugs
- Where
- 7 sites in China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Grand Johamu Pharmaceutical Company, Ltd.